Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04328961 · ClinicalTrials.gov registry record · Phase 2
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 943
- Enrollment target
NCT04328961 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 943 participants.
The verdict
NCT04328961, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 943 participants
- Enrollment target
Study Summary
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. Eligible participants will be enrolled and randomized to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).
Interventions
- DRUG Ascorbic Acid
- DRUG Hydroxychloroquine Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 943 participants |
| Start Date | 2020-03-31 |
| Est. Completion | 2020-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04328961
The ClinicalTrials.gov registry entry for NCT04328961 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 943 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ascorbic Acid is the first listed.
NCT04328961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04328961 about?
NCT04328961 is a clinical study titled "Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)". This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. ...
What is the current status of trial NCT04328961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 943 participants. The study started on 2020-03-31. Estimated completion is 2020-10-08.
What interventions are being tested in trial NCT04328961?
The interventions under investigation include: Ascorbic Acid (DRUG), Hydroxychloroquine Sulfate (DRUG).
Who is sponsoring clinical trial NCT04328961?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.